European Patent Office

T 2345/17 (HRT Formulations / NOVO NORDISK) of 25.09.2023

European Case Law Identifier
ECLI:EP:BA:2023:T234517.20230925
Date of decision
25 September 2023
Case number
T 2345/17
Petition for review of
-
Application number
04762858.1
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
HRT FORMULATIONS
Applicant name
Novo Nordisk Health Care AG
Opponent name
Actavis Group PTC ehf
Generics [UK] Ltd (trading as Mylan)
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 56Rules of procedure of the Boards of Appeal Art 12(4)
Keywords
All requests - inventive step - (no)
Catchword
-
Cited cases
T 1323/17
Citing cases
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.